{"cord_uid":"n85jp1f3", "sourcedb":"PMC", "sourceid":"PMC6921433", "divid":11, "text":"First, as was the case with Zika virus, many stakeholders are likely to be interested in addressing an emerging infectious disease in the midst of an outbreak, making it difficult to determine how much value an HCT would add. Within a year of the panel's report, it became clear that an efficacy trial would be extremely difficult to conduct giving the declining numbers and unpredictability of Zika outbreaks, and the initial uncertainty about the value of a Zika HCT was resolved [17] . One possibility, then, is that riskier HCTs of emerging infectious diseases may not be part of the first-line response to an epidemic, but potentially valuable tools in the arsenal that could be deployed when other possibilities have been exhausted.", "project":"cdlai_CORD-19", "denotations":[]}